» Articles » PMID: 2816498

Parabiosis Suggests a Humoral Factor is Involved in X-linked Hypophosphatemia in Mice

Overview
Date 1989 Aug 1
PMID 2816498
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

Reduced renal tubular reabsorption of phosphate of unknown etiology is characteristic of X-linked hypophosphatemia in both humans and mice. To test whether a humoral abnormality is involved in the renal effect, parabiosis was performed between Hyp and normal mice at 4 weeks of age. The normal mice joined to Hyp mice showed a progressive diminution of plasma phosphate over the next 3 weeks to approach the level of the Hyp mice. These normal mice had a greater renal phosphate excretion index (urine P/plasma P/urine creatinine) than normal-normal pairs, thus suggesting a reduced renal tubular reabsorption of phosphate. At the same time the expected rises in plasma calcium and plasma 1,25-dihydroxyvitamin D did not occur. There was a significant reduction in their femoral mineral content but not in their femoral length or body growth relative to normal-normal pairs. This change in renal handling of phosphate was specific since the urinary losses of potassium and magnesium were not significantly changed. Separation of normal-Hyp pairs 3 or 6 weeks after parabiosis caused the normal mice to achieve normal plasma phosphate levels within 24 h. At 48 h and 7 days after separation these normal mice had plasma phosphate levels higher than normal mice separated from normal-normal pairs. In summary, the data suggest the presence of a phosphaturic factor in the Hyp mice that can cross a parabiotic union into normal mice and induce many of the symptoms of X-linked hypophosphatemia.

Citing Articles

Bone marrow sinusoidal endothelial cells are a site of Fgf23 upregulation in a mouse model of iron deficiency anemia.

Li X, Lozovatsky L, Tommasini S, Fretz J, Finberg K Blood Adv. 2023; 7(17):5156-5171.

PMID: 37417950 PMC: 10480544. DOI: 10.1182/bloodadvances.2022009524.


Osteomalacia in Adults: A Practical Insight for Clinicians.

Arboleya L, Brana I, Pardo E, Loredo M, Queiro R J Clin Med. 2023; 12(7).

PMID: 37048797 PMC: 10094844. DOI: 10.3390/jcm12072714.


New concepts in regulation and function of the FGF23.

Dastghaib S, Koohpeyma F, Shams M, Saki F, Alizadeh A Clin Exp Med. 2022; 23(4):1055-1066.

PMID: 35708778 DOI: 10.1007/s10238-022-00844-x.


Disorders of phosphate homeostasis in children, part 1: primer on mineral ion homeostasis and the roles of phosphate in skeletal biology.

Shore R Pediatr Radiol. 2022; 52(12):2278-2289.

PMID: 35536415 DOI: 10.1007/s00247-022-05374-y.


Analysis of the Contribution of Proprotein Convertases to the Processing of FGF23.

Al Rifai O, Susan-Resiga D, Essalmani R, Creemers J, Seidah N, Ferron M Front Endocrinol (Lausanne). 2021; 12:690681.

PMID: 34149625 PMC: 8213403. DOI: 10.3389/fendo.2021.690681.